| ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier H Bronger, J König, K Kopplow, HH Steiner, R Ahmadi, C Herold-Mende, ... Cancer research 65 (24), 11419-11428, 2005 | 371 | 2005 |
| CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer H Bronger, J Singer, C Windmüller, U Reuning, D Zech, C Delbridge, ... British journal of cancer 115 (5), 553-563, 2016 | 231 | 2016 |
| Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping JD Wulfkuhle, D Berg, C Wolff, R Langer, K Tran, J Illi, V Espina, ... Clinical cancer research 18 (23), 6426-6435, 2012 | 124 | 2012 |
| Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: a systematic review and meta-analysis of individual patient data PA Cohen, A Powell, S Böhm, CB Gilks, CJR Stewart, TM Meniawy, ... Gynecologic oncology 154 (2), 441-448, 2019 | 95 | 2019 |
| Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer H Bronger, S Kraeft, U Schwarz-Boeger, C Cerny, A Stöckel, S Avril, ... Breast Cancer Research 14, 1-14, 2012 | 82 | 2012 |
| Prognosis of ovarian cancer is associated with effector memory CD8+ T cell accumulation in ascites, CXCL9 levels and activation-triggered signal transduction in T … S Lieber, S Reinartz, H Raifer, F Finkernagel, T Dreyer, H Bronger, ... Oncoimmunology 7 (5), e1424672, 2018 | 78 | 2018 |
| Sarcopenia in advanced serous ovarian cancer H Bronger, P Hederich, A Hapfelmeier, S Metz, PB Noël, M Kiechle, ... International Journal of Gynecologic Cancer 27 (2), 2017 | 72 | 2017 |
| Signalling networks associated with urokinase‐type plasminogen activator (uPA) and its inhibitor PAI‐1 in breast cancer tissues: new insights from protein microarray analysis C Wolff, K Malinowsky, D Berg, K Schragner, T Schuster, A Walch, ... The Journal of pathology 223 (1), 54-63, 2011 | 61 | 2011 |
| MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer M Raychaudhuri, H Bronger, T Buchner, M Kiechle, W Weichert, S Avril Breast cancer research and treatment 162, 511-521, 2017 | 60 | 2017 |
| Intratumoral heterogeneity of microRNA expression in breast cancer M Raychaudhuri, T Schuster, T Buchner, K Malinowsky, H Bronger, ... The Journal of Molecular Diagnostics 14 (4), 376-384, 2012 | 54 | 2012 |
| uPA and PAI-1-related signaling pathways differ between primary breast cancers and lymph node metastases K Malinowsky, C Wolff, D Berg, T Schuster, A Walch, H Bronger, ... Translational oncology 5 (2), 98-IN3, 2012 | 37 | 2012 |
| Increased PDGFR-beta and VEGFR-2 protein levels are associated with resistance to platinum-based chemotherapy and adverse outcome of ovarian cancer patients S Avril, Y Dincer, K Malinowsky, C Wolff, S Gündisch, A Hapfelmeier, ... Oncotarget 8 (58), 97851, 2017 | 35 | 2017 |
| Induction of cathepsin B by the CXCR3 chemokines CXCL9 and CXCL10 in human breast cancer cells H Bronger, A Karge, T Dreyer, D Zech, S Kraeft, S Avril, M Kiechle, ... Oncology Letters 13 (6), 4224-4230, 2017 | 35 | 2017 |
| Kallikrein-related peptidases represent attractive therapeutic targets for ovarian cancer D Loessner, P Goettig, S Preis, J Felber, H Bronger, JA Clements, J Dorn, ... Expert Opinion on Therapeutic Targets 22 (9), 745-763, 2018 | 34 | 2018 |
| OVSCORE‑a validated score to identify ovarian cancer patients not suitable for primary surgery J Dorn, H Bronger, R Kates, J Slotta‑Huspenina, B Schmalfeldt, M Kiechle, ... Oncology Letters 9 (1), 418-424, 2015 | 33 | 2015 |
| Proteolytic chemokine cleavage as a regulator of lymphocytic infiltration in solid tumors H Bronger, V Magdolen, P Goettig, T Dreyer Cancer and Metastasis Reviews 38, 417-430, 2019 | 30 | 2019 |
| CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer S Seitz, TF Dreyer, C Stange, K Steiger, R Bräuer, L Scheutz, G Multhoff, ... British Journal of Cancer 126 (10), 1470-1480, 2022 | 28 | 2022 |
| Profiling signalling pathways in formalin‐fixed and paraffin‐embedded breast cancer tissues reveals cross‐talk between EGFR, HER2, HER3 and uPAR D Berg, C Wolff, K Malinowsky, K Tran, A Walch, H Bronger, T Schuster, ... Journal of Cellular Physiology 227 (1), 204-212, 2012 | 28 | 2012 |
| Protein microarray-based comparison of HER2, estrogen receptor, and progesterone receptor status in core biopsies and surgical specimens from FFPE breast cancer tissues D Berg, R Langer, K Tran, A Walch, T Schuster, H Bronger, KF Becker Applied Immunohistochemistry & Molecular Morphology 19 (4), 300-305, 2011 | 28 | 2011 |
| CXCR3 mediates ascites-directed tumor cell migration and predicts poor outcome in ovarian cancer patients C Windmüller, D Zech, S Avril, M Boxberg, T Dawidek, B Schmalfeldt, ... Oncogenesis 6 (5), e331-e331, 2017 | 27 | 2017 |
Karl-Friedrich BeckerProfessor, Experimental Pathology, Biobank, Technische Universität MünchenDirección de correo verificada de tum.de
